CHICAGO--(BUSINESS WIRE)--VectorBuilder, a global leader in gene delivery solutions, announced today that its Chief Scientist, Dr. Bruce Lahn, has been honored as a PharmaVoice 100 winner. This prestigious annual list recognizes the most inspiring and influential leaders in the life sciences industry.
“It is a great privilege to be recognized alongside such influential figures in life sciences,” said Dr. Bruce Lahn. "This recognition reflects the collaborative and innovative spirit at the heart of VectorBuilder. We are committed to accelerating the pace of gene therapy development through cutting-edge technologies and custom-built solutions that are transforming how diseases are treated. As a team, we strive to empower researchers and clinicians worldwide with the tools they need to push the boundaries of modern medicine. This award reaffirms our dedication to driving innovation in gene delivery systems that can unlock new treatments for some of the world’s most challenging health conditions.”
Dr. Lahn founded VectorBuilder with a vision to revolutionize gene therapy by simplifying and streamlining the development of gene delivery systems. His background as a renowned geneticist, combined with his passion for innovation, has driven the company's rapid growth. Under his leadership, VectorBuilder has become a global leader in the gene therapy space, offering groundbreaking solutions that empower researchers to push the boundaries of medical science.
VectorBuilder is a global CRO (Contract Research Organization) and CDMO (Contract Development and Manufacturing Organization) providing comprehensive, end-to-end gene delivery solutions, including custom vector design, plasmid production, and viral vector manufacturing. With a strong foundation in GMP manufacturing, VectorBuilder has earned the trust of over 4,500 academic institutions and biotech/pharmaceutical companies worldwide.
PharmaVoice100 honorees are selected from a pool of nominations submitted by readers and colleagues, evaluated by the PharmaVoice team, then categorized into 10 distinct groups: Standout Leaders, Cancer Care Visionaries, Cardiometabolic All-Stars, Trailblazers, Biotech Pathfinders, Rare Disease Warriors, Tech and AI Wizards, Clinical Trial Pros, Patient Champions, and Cell and Gene Therapy Pioneers. Each winner represents the transformative impact of the pharmaceutical industry in their own unique way.
“These honorees are inspirations. Their teams look to them for guidance, their patients for support, and their organizations for direction. Each winner represents progress toward a healthier future for everyone that is bolstered by science and technological advancements. We are excited to recognize their contributions through this annual list,” said Meagan Parrish, lead editor of PharmaVoice.
Since 2005, the PharmaVoice 100 has become one of the publication’s most anticipated features. From academia and nonprofits to Big Pharma, startups and tech companies, it is the only awards program in the industry that honors individuals from all sectors of life sciences. These honorees, from the clinic to the C-suite, are making meaningful contributions to their fields and striving to improve outcomes for patients around the world.
About VectorBuilder
VectorBuilder is a global leader in gene delivery technologies. As a trusted partner in thousands of labs and biotech/pharma companies around the world, VectorBuilder is a one-stop shop for the design, development and optimization of gene delivery solutions from basic research to clinical applications. Its award-winning Vector Design Studio is a transformative innovation that allows researchers to easily design and order custom vectors online, freeing them from the tedious work of cloning and packaging vectors in the lab. The global company boasts high-throughput vector production capacity, vast vector and component inventories, one-on-one CRO solutions that include advanced AAV capsid engineering capabilities and state-of-the-art GMP facilities. With leading R&D and CDMO manufacturing capacity, the VectorBuilder team strives to provide the most effective gene delivery solutions and develop new tools for life sciences research and genetic medicine.
About PharmaVoice
PharmaVoice is a leading industry publication operated by Industry Dive. Our stories deliver the most important voices and ideas in the life sciences to industry leaders.
About Industry Dive
Industry Dive, an Informa business, is a leading business journalism company. Over 14 million decision-makers across 20+ competitive industries rely on our exclusive insight and analysis delivered through more than 30 publications.
